Sunshine Biopharma Inc.: updates and filings

SBFMNASDAQHealthcare · Pharmaceutical Preparations

Price

$2.54

November 17, 2026Market cap $2.1M

What Ploutos Investor adds for Sunshine Biopharma

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 16 fiscal years, from 2010
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 52 daysAround Jan 8, 2027 · for Q4 2026

An estimate from when it has reported before, and the timing has varied a little. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Apr 3, 2026 latest annualNov 12, 2026 latest quarterly
  • Nov 13, 2026Additional annual meeting material
    FormDEFA14A
  • Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 12, 2026Annual meeting proxy statement
    FormDEF 14A
  • Nov 10, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 27, 2026DEFINITIVE INFORMATION STATEMENT
    FormDEF 14C
  • Oct 14, 2026PRELIMINARY INFORMATION STATEMENT
    FormPRE 14C
  • Oct 14, 2026Shareholder vote
    Form8-K
  • Oct 14, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Oct 13, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Oct 9, 2026Material agreement entered, other material events
    Form8-K
  • Oct 7, 2026Filing
    FormEFFECT
  • Oct 5, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 2, 2026FORM S-1
    FormS-1
  • Sep 28, 2026DEFINITIVE INFORMATION STATEMENT
    FormDEF 14C
  • Sep 24, 2026Filing
    FormDRS
  • Sep 16, 2026PRELIMINARY PROXY
    FormPRE 14C
  • Sep 16, 2026Shareholder vote
    Form8-K
  • Sep 11, 2026Other material events
    Form8-K
  • Sep 8, 2026Filing
    FormEFFECT
  • Aug 28, 2026FORM S-1
    FormS-1
  • Aug 28, 2026Officer or director change
    Form8-K
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 13, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 3, 2026Other material events
    Form8-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since May 25, 2007.

The full analysis

What do Sunshine Biopharma's filings show?

The filings are where every one of Sunshine Biopharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.